Bio-Rad Introduces EveryBlot Blocking Buffer that Offers 5-Minute Blocking Time and Greater Sensitivity for Western Blots

Date: 
11/11/19

EveryBlot Blocking Buffer provides 5-minute blocking and maximum sensitivity for western blots, regardless of the detection method.

HERCULES, Calif. — November 11, 2019 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of EveryBlot Blocking Buffer, a western blot blocking reagent that offers 5-minute blocking time and produces higher signal and lower background levels resulting in greater sensitivity for western blots compared to other available blocking buffers.

When attempting to detect a new protein target, researchers often optimize several variables including the use of specific blocking buffers (reagents) when performing western blots. For example, many blocking buffers are optimized for specific detection methods such as chemiluminescence or fluorescence detection and some buffers may not be compatible for detection of some targets. EveryBlot offers superior sensitivity and low background with both chemiluminescent and fluorescence detection across a wide range of targets. In addition, available blocking buffers require blocking times of up to an hour, while EveryBlot Blocking Buffer completes the blocking step in five minutes.

"EveryBlot works with all detection methods and has been tested for compatibility across a wide range of protein targets, which should help eliminate the worry that comes when attempting to detect a new protein on a western blot," said Paul Liu, Bio-Rad Product Manager, Western Blotting.

Key Benefits of EveryBlot Buffer

  • Offers 5-minute blocking time, shortening the duration of the immunodetection step
  • Offers higher signal and lower background levels therefore greater sensitivity than blots blocked with other available buffers
  • Prevents non-specific binding to increase sensitivity
  • Compatible with all detection methods as well as for detection of phosphorylated targets, which eliminates the need for optimization

To learn more about EveryBlot Blocking Buffer, please visit www.bio-rad.com/SeeEveryBlot

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit www.bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Press Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
520-240-7000
Tina_Cuccia@bio-rad.com